<?xml version='1.0' encoding='utf-8'?>
<document id="22057855"><sentence text="The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer."><entity charOffset="14-24" id="DDI-PubMed.22057855.s1.e0" text="bexarotene" /><entity charOffset="28-40" id="DDI-PubMed.22057855.s1.e1" text="atorvastatin" /><entity charOffset="91-101" id="DDI-PubMed.22057855.s1.e2" text="bexarotene" /><pair ddi="false" e1="DDI-PubMed.22057855.s1.e0" e2="DDI-PubMed.22057855.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22057855.s1.e0" e2="DDI-PubMed.22057855.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22057855.s1.e0" e2="DDI-PubMed.22057855.s1.e2" /><pair ddi="false" e1="DDI-PubMed.22057855.s1.e1" e2="DDI-PubMed.22057855.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22057855.s1.e1" e2="DDI-PubMed.22057855.s1.e2" /></sentence><sentence text="Bexarotene (Targretin(®) capsules) is a retinoid-X-receptor agonist and an inducer of CYP3A4-mediated metabolism"><entity charOffset="0-10" id="DDI-PubMed.22057855.s2.e0" text="Bexarotene" /></sentence><sentence text=" This phase I trial evaluated the pharmacokinetic (PK) and drug-drug interactions of bexarotene with chemotherapy and a lipid-lowering agent (atorvastatin or fenofibrate)"><entity charOffset="85-95" id="DDI-PubMed.22057855.s3.e0" text="bexarotene" /><entity charOffset="142-154" id="DDI-PubMed.22057855.s3.e1" text="atorvastatin" /><entity charOffset="158-169" id="DDI-PubMed.22057855.s3.e2" text="fenofibrate" /><pair ddi="false" e1="DDI-PubMed.22057855.s3.e0" e2="DDI-PubMed.22057855.s3.e0" /><pair ddi="false" e1="DDI-PubMed.22057855.s3.e0" e2="DDI-PubMed.22057855.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22057855.s3.e0" e2="DDI-PubMed.22057855.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22057855.s3.e1" e2="DDI-PubMed.22057855.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22057855.s3.e1" e2="DDI-PubMed.22057855.s3.e2" /></sentence><sentence text=" This trial was run in parallel with phase III trials of the combinations to determine whether repeated doses of bexarotene capsules affect the pharmacokinetics (PK) of the chemotherapeutic or the lipid-lowering agents"><entity charOffset="113-123" id="DDI-PubMed.22057855.s4.e0" text="bexarotene" /></sentence><sentence text="" /><sentence text="Patients (n = 48) with advanced non-small cell lung cancer were treated with repetitive cycles of either paclitaxel/carboplatin or cisplatin/vinorelbine chemotherapy, bexarotene (400 mg/m(2)/day) administered continuously starting on day 4 of chemotherapy, and a lipid-lowering drug, either atorvastatin or fenofibrate, starting at least 5 days before chemotherapy due to hypertriglyceridemia induced by bexarotene"><entity charOffset="105-115" id="DDI-PubMed.22057855.s6.e0" text="paclitaxel" /><entity charOffset="116-127" id="DDI-PubMed.22057855.s6.e1" text="carboplatin" /><entity charOffset="131-140" id="DDI-PubMed.22057855.s6.e2" text="cisplatin" /><entity charOffset="141-152" id="DDI-PubMed.22057855.s6.e3" text="vinorelbine" /><entity charOffset="167-177" id="DDI-PubMed.22057855.s6.e4" text="bexarotene" /><entity charOffset="291-303" id="DDI-PubMed.22057855.s6.e5" text="atorvastatin" /><entity charOffset="307-318" id="DDI-PubMed.22057855.s6.e6" text="fenofibrate" /><entity charOffset="404-414" id="DDI-PubMed.22057855.s6.e7" text="bexarotene" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e0" e2="DDI-PubMed.22057855.s6.e0" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e0" e2="DDI-PubMed.22057855.s6.e1" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e0" e2="DDI-PubMed.22057855.s6.e2" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e0" e2="DDI-PubMed.22057855.s6.e3" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e0" e2="DDI-PubMed.22057855.s6.e4" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e0" e2="DDI-PubMed.22057855.s6.e5" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e0" e2="DDI-PubMed.22057855.s6.e6" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e0" e2="DDI-PubMed.22057855.s6.e7" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e1" e2="DDI-PubMed.22057855.s6.e1" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e1" e2="DDI-PubMed.22057855.s6.e2" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e1" e2="DDI-PubMed.22057855.s6.e3" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e1" e2="DDI-PubMed.22057855.s6.e4" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e1" e2="DDI-PubMed.22057855.s6.e5" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e1" e2="DDI-PubMed.22057855.s6.e6" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e1" e2="DDI-PubMed.22057855.s6.e7" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e2" e2="DDI-PubMed.22057855.s6.e2" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e2" e2="DDI-PubMed.22057855.s6.e3" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e2" e2="DDI-PubMed.22057855.s6.e4" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e2" e2="DDI-PubMed.22057855.s6.e5" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e2" e2="DDI-PubMed.22057855.s6.e6" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e2" e2="DDI-PubMed.22057855.s6.e7" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e3" e2="DDI-PubMed.22057855.s6.e3" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e3" e2="DDI-PubMed.22057855.s6.e4" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e3" e2="DDI-PubMed.22057855.s6.e5" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e3" e2="DDI-PubMed.22057855.s6.e6" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e3" e2="DDI-PubMed.22057855.s6.e7" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e4" e2="DDI-PubMed.22057855.s6.e4" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e4" e2="DDI-PubMed.22057855.s6.e5" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e4" e2="DDI-PubMed.22057855.s6.e6" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e4" e2="DDI-PubMed.22057855.s6.e7" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e5" e2="DDI-PubMed.22057855.s6.e5" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e5" e2="DDI-PubMed.22057855.s6.e6" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e5" e2="DDI-PubMed.22057855.s6.e7" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e6" e2="DDI-PubMed.22057855.s6.e6" /><pair ddi="false" e1="DDI-PubMed.22057855.s6.e6" e2="DDI-PubMed.22057855.s6.e7" /></sentence><sentence text=" Extensive plasma sampling to characterize the PK profiles of the lipid-lowering drugs, relevant chemotherapy agents was performed on day 1 (without bexarotene) and during chemotherapy cycles 2 or 3 (with bexarotene)"><entity charOffset="149-159" id="DDI-PubMed.22057855.s7.e0" text="bexarotene" /><entity charOffset="205-215" id="DDI-PubMed.22057855.s7.e1" text="bexarotene" /><pair ddi="false" e1="DDI-PubMed.22057855.s7.e0" e2="DDI-PubMed.22057855.s7.e0" /><pair ddi="false" e1="DDI-PubMed.22057855.s7.e0" e2="DDI-PubMed.22057855.s7.e1" /></sentence><sentence text="" /><sentence text="Here, we report the drug-drug interactions between the lipid-lowering agents and bexarotene"><entity charOffset="81-91" id="DDI-PubMed.22057855.s9.e0" text="bexarotene" /></sentence><sentence text=" Mean atorvastatin clearance and dose-corrected AUC values were reduced by nearly 50% with the addition of concomitant bexarotene"><entity charOffset="6-18" id="DDI-PubMed.22057855.s10.e0" text="atorvastatin" /><entity charOffset="119-129" id="DDI-PubMed.22057855.s10.e1" text="bexarotene" /><pair ddi="false" e1="DDI-PubMed.22057855.s10.e0" e2="DDI-PubMed.22057855.s10.e0" /><pair ddi="false" e1="DDI-PubMed.22057855.s10.e0" e2="DDI-PubMed.22057855.s10.e1" /></sentence><sentence text=" As fenofibrate was less effective at controlling hypertriglyceridemia, too few patients received this agent to make any meaningful conclusions about drug-drug interactions"><entity charOffset="4-15" id="DDI-PubMed.22057855.s11.e0" text="fenofibrate" /></sentence><sentence text="" /><sentence text="A drug-drug interaction was seen in this trial with bexarotene co-administration leading to a significant reduction in the AUC of atorvastatin"><entity charOffset="52-62" id="DDI-PubMed.22057855.s13.e0" text="bexarotene" /><entity charOffset="130-142" id="DDI-PubMed.22057855.s13.e1" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.22057855.s13.e0" e2="DDI-PubMed.22057855.s13.e0" /><pair ddi="false" e1="DDI-PubMed.22057855.s13.e0" e2="DDI-PubMed.22057855.s13.e1" /></sentence><sentence text=" The likely mechanism for this interaction is through induction of CYP3A4 by bexarotene given the role of this enzyme in the metabolism of atorvastatin"><entity charOffset="139-151" id="DDI-PubMed.22057855.s14.e0" text="atorvastatin" /></sentence><sentence text=" Knowledge of this interaction is important for optimizing lipid management with atorvastatin for patients receiving bexarotene"><entity charOffset="81-93" id="DDI-PubMed.22057855.s15.e0" text="atorvastatin" /><entity charOffset="117-127" id="DDI-PubMed.22057855.s15.e1" text="bexarotene" /><pair ddi="false" e1="DDI-PubMed.22057855.s15.e0" e2="DDI-PubMed.22057855.s15.e0" /><pair ddi="false" e1="DDI-PubMed.22057855.s15.e0" e2="DDI-PubMed.22057855.s15.e1" /></sentence><sentence text="" /></document>